FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff Sells 18,400 Shares

FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,400 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $45.65, for a total transaction of $839,960.00. Following the transaction, the chief executive officer now directly owns 2,379,710 shares of the company’s stock, valued at $108,633,761.50. The sale was disclosed in a document filed with the SEC, which is available through this link.

Shares of NASDAQ FGEN traded down $1.57 during midday trading on Wednesday, hitting $43.52. The company’s stock had a trading volume of 862,880 shares, compared to its average volume of 724,002. FibroGen Inc has a 1-year low of $33.51 and a 1-year high of $62.00. The business has a fifty day simple moving average of $45.81. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.16 and a current ratio of 6.16. The firm has a market cap of $3.98 billion, a price-to-earnings ratio of -42.25 and a beta of 1.86.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $1.26 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $1.75. FibroGen had a net margin of 13.90% and a return on equity of 9.62%. The business had revenue of $191.57 million during the quarter, compared to analyst estimates of $29.03 million. During the same period in the previous year, the business posted ($0.28) EPS. The company’s quarterly revenue was up 335.9% on a year-over-year basis. On average, equities research analysts forecast that FibroGen Inc will post -1.09 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Norges Bank acquired a new position in shares of FibroGen in the 4th quarter valued at about $32,604,000. New York State Common Retirement Fund boosted its holdings in shares of FibroGen by 124.7% in the 1st quarter. New York State Common Retirement Fund now owns 164,963 shares of the biopharmaceutical company’s stock valued at $8,966,000 after buying an additional 91,563 shares during the period. Lindbrook Capital LLC boosted its holdings in shares of FibroGen by 150.0% in the 1st quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 300 shares during the period. Fiera Capital Corp acquired a new position in shares of FibroGen in the 1st quarter valued at about $34,161,000. Finally, Adams Diversified Equity Fund Inc. acquired a new position in shares of FibroGen in the 1st quarter valued at about $212,000. 64.67% of the stock is owned by institutional investors and hedge funds.

Several research analysts have weighed in on the stock. Goldman Sachs Group reissued a “neutral” rating and set a $45.00 price objective on shares of FibroGen in a report on Wednesday, May 29th. Piper Jaffray Companies reissued a “positive” rating and set a $40.00 price objective (down from $65.00) on shares of FibroGen in a report on Monday, May 27th. Zacks Investment Research raised shares of FibroGen from a “hold” rating to a “buy” rating and set a $51.00 price objective for the company in a report on Tuesday. Mizuho reissued a “buy” rating and set a $65.00 price objective on shares of FibroGen in a report on Sunday. Finally, TheStreet lowered shares of FibroGen from a “c-” rating to a “d+” rating in a report on Friday, May 24th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. FibroGen currently has a consensus rating of “Buy” and an average price target of $61.00.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Featured Article: Total Return

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply